JP2016502991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502991A5 JP2016502991A5 JP2015547039A JP2015547039A JP2016502991A5 JP 2016502991 A5 JP2016502991 A5 JP 2016502991A5 JP 2015547039 A JP2015547039 A JP 2015547039A JP 2015547039 A JP2015547039 A JP 2015547039A JP 2016502991 A5 JP2016502991 A5 JP 2016502991A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- pharmaceutical
- agents
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 206010027654 Allergic conditions Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 229960001120 levocabastine Drugs 0.000 claims description 6
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000006068 taste-masking agent Substances 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 3
- ZCGOMHNNNFPNMX-YHYDXASRSA-N Levocabastinum Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)C2CCC(CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-YHYDXASRSA-N 0.000 claims description 2
- 206010039094 Rhinitis perennial Diseases 0.000 claims description 2
- 208000036284 Rhinitis seasonal Diseases 0.000 claims description 2
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- -1 fluticasone furan carboxylate ester Chemical class 0.000 claims description 2
- 229960001828 levocabastine hydrochloride Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940009662 edetate Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical group O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737927P | 2012-12-17 | 2012-12-17 | |
| US61/737,927 | 2012-12-17 | ||
| US201361867794P | 2013-08-20 | 2013-08-20 | |
| US61/867,794 | 2013-08-20 | ||
| PCT/EP2013/076486 WO2014095602A1 (en) | 2012-12-17 | 2013-12-13 | Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502991A JP2016502991A (ja) | 2016-02-01 |
| JP2016502991A5 true JP2016502991A5 (enExample) | 2017-01-05 |
| JP6294893B2 JP6294893B2 (ja) | 2018-03-14 |
Family
ID=49759334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547039A Expired - Fee Related JP6294893B2 (ja) | 2012-12-17 | 2013-12-13 | 炎症性及び／又はアレルギー性の状態を治療するためのレボカバスチンとフルチカゾンフランカルボン酸エステルとの併用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9675624B2 (enExample) |
| EP (1) | EP2931249B1 (enExample) |
| JP (1) | JP6294893B2 (enExample) |
| KR (1) | KR20150095896A (enExample) |
| CN (1) | CN104869980A (enExample) |
| AU (1) | AU2013363876B9 (enExample) |
| BR (1) | BR112015014262A8 (enExample) |
| CA (1) | CA2893654A1 (enExample) |
| ES (1) | ES2722926T3 (enExample) |
| RU (1) | RU2652352C2 (enExample) |
| WO (1) | WO2014095602A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102015206486B4 (de) * | 2015-04-10 | 2023-06-01 | Adidas Ag | Schuh, insbesondere Sportschuh, und Verfahren zur Herstellung desselben |
| USD783264S1 (en) | 2015-09-15 | 2017-04-11 | Adidas Ag | Shoe |
| JPWO2019235616A1 (ja) * | 2018-06-08 | 2021-06-17 | 東興薬品工業株式会社 | フルチカゾンフランカルボン酸エステル点鼻組成物 |
| LT3769753T (lt) * | 2019-07-23 | 2022-05-10 | Nicox Ophthalmics, Inc. | Sterilių oftalmologinių vandeninių flutikazono propionato a formos nanokristalų suspensijų gavimo būdas |
| RU2736082C1 (ru) * | 2019-12-02 | 2020-11-11 | федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Фармацевтическая композиция противоаллергического и противовоспалительного действия для интраназального применения |
| WO2021255622A1 (en) * | 2020-06-15 | 2021-12-23 | Alkem Laboratories Limited | Combination of alcaftadine and a corticosteroid |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| PL2486942T3 (pl) * | 2004-11-24 | 2019-05-31 | Meda Pharmaceuticals Inc | Kompozycje zawierające azelastynę oraz sposoby ich stosowania |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| CL2008003036A1 (es) * | 2007-10-16 | 2009-05-08 | Glaxo Group Ltd | Composicion farmaceutica acuosa que comprende 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4-{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona; envase que la comprende; y uso para el tratamiento de enfermedades inflamatorias y/o alergicas tal como rinitis alergica. |
| CN101757625A (zh) | 2008-11-28 | 2010-06-30 | 天津金耀集团有限公司 | 环糊精包合皮质激素和h1受体拮抗剂的鼻用药物组合物 |
-
2013
- 2013-12-13 WO PCT/EP2013/076486 patent/WO2014095602A1/en not_active Ceased
- 2013-12-13 EP EP13803046.5A patent/EP2931249B1/en active Active
- 2013-12-13 JP JP2015547039A patent/JP6294893B2/ja not_active Expired - Fee Related
- 2013-12-13 AU AU2013363876A patent/AU2013363876B9/en not_active Ceased
- 2013-12-13 US US14/652,037 patent/US9675624B2/en not_active Expired - Fee Related
- 2013-12-13 ES ES13803046T patent/ES2722926T3/es active Active
- 2013-12-13 CA CA2893654A patent/CA2893654A1/en not_active Abandoned
- 2013-12-13 BR BR112015014262A patent/BR112015014262A8/pt not_active Application Discontinuation
- 2013-12-13 KR KR1020157019106A patent/KR20150095896A/ko not_active Withdrawn
- 2013-12-13 RU RU2015121039A patent/RU2652352C2/ru not_active IP Right Cessation
- 2013-12-13 CN CN201380066132.8A patent/CN104869980A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502991A5 (enExample) | ||
| US8709508B2 (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
| CA2728386C (en) | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | |
| JP2005521673A5 (enExample) | ||
| JP2012522783A5 (enExample) | ||
| JP2016534153A5 (enExample) | ||
| RU2015121039A (ru) | Комбинация левокабастина и флутиказона фуроата для лечения воспалительных и/или аллергических состояний | |
| US20090312724A1 (en) | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions | |
| JP2009544665A5 (enExample) | ||
| JP2015518006A5 (enExample) | ||
| JP2013513612A5 (enExample) | ||
| HRP20211515T1 (hr) | Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni | |
| WO2009003199A1 (en) | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | |
| JP2016534142A5 (enExample) | ||
| JP2012046483A5 (enExample) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2012520882A5 (enExample) | ||
| SI3193835T1 (en) | Liquid inhalation preparation containing rpl554 | |
| EP3069720A8 (en) | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases | |
| JP5785360B2 (ja) | 炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤 | |
| JP2016531949A5 (enExample) | ||
| HRP20201652T1 (hr) | Metoda za prevenciju i/ili liječenje oštećenja kognitivnih funkcija i neuroinflamacije povezanih sa starenjem | |
| MX390671B (es) | Composicion de suspension oftalmica. | |
| RU2015128496A (ru) | Лечение аллергического ринита с использованием комбинации мометазона и олопатадина | |
| JP2013534527A5 (enExample) |